Merck to stop developing hep.-C drugs; FDA approves new Lilly breast-cancer drug; California bill would outlaw co-pay cards
The FDA plans to review orphan drug backlog; drugmaker supported charity helped patients pay for donor's drugs; low dose Xarelto gets Priority Review
Funding for patient-assistance charities makes up 7% of operating expenses for drugmakers; Avanir ad under fire; Trump to consider Medicare rebates
PBMs' use of "clawbacks" prompt lawsuits; Merck's experimental antiviral drug prevents infection; EMA recommends Novartis' lung-cancer combo drug
In this sponsored podcast, MM&M's Larry Dobrow speaks with Robert Leedom, senior analytics consultant at TrialCard, and Paul LeVine, VP of analytic services for TrialCard, about how to reach patients by leveraging brand data.
Will this payer pressure pose an existential threat to co-pay cards even though patients love them?
The drugmaker marketed a co-pay assistance voucher that failed to provide any risk information about its drug Ulesfia.
If you truly understand who your high writers and compliant patients are, you'll understand when and how to communicate with prospects that look and act like them.
Valeant CEO takes medical leave; average asthma rates for US children trends downward; drugmakers paid $7 billion for coupons and co-pay cards in 2015
Amgen reportedly asks Repatha patients seeking financial assistance for personal health information; Valeant faces more scrutiny of business model; the FDA approves new J&J cancer drug
Recent deals show these companies are expanding their EHR networks, and the number of physicians who gain access to copay coupons, vouchers and other forms of assistance.